Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis
Roberta Caputo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Alessandro Rizzo(Istituto Tumori Bari), Francesco Nuzzo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Alessandra Fabi(Agostino Gemelli University Polyclinic), Ida Paris(Agostino Gemelli University Polyclinic), Claudia Martinelli(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Daniela Cianniello(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Nicoletta Staropoli(Magna Graecia University), Rodolfo Cangiano, Giuseppe Buono(Federico II University Hospital), Salvatore Turano(Azienda Ospedaliera di Cosenza), Michela Piezzo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Francesco Pantano(Università Campus Bio-Medico)
Cited by 74
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Rechallenge for Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan
|JAMA Oncology|2018|418
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
|Cancer Treatment Reviews|2018|282